Ustekinumab (UST)
Ustekinumab (UST) is a pharmaceutical drug with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
No phase data available
Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
3
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Status
Recent Activity
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
Clinical Trials (5)
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5